EA202091057A2 - Способы и композиции для лечения нарушений, ассоциированных со старением - Google Patents

Способы и композиции для лечения нарушений, ассоциированных со старением

Info

Publication number
EA202091057A2
EA202091057A2 EA202091057A EA202091057A EA202091057A2 EA 202091057 A2 EA202091057 A2 EA 202091057A2 EA 202091057 A EA202091057 A EA 202091057A EA 202091057 A EA202091057 A EA 202091057A EA 202091057 A2 EA202091057 A2 EA 202091057A2
Authority
EA
Eurasian Patent Office
Prior art keywords
aging
methods
compositions
treatment
disorders associated
Prior art date
Application number
EA202091057A
Other languages
English (en)
Other versions
EA202091057A3 (ru
Inventor
Антон Висс-Корэй
Саул А. Вилледа
Кароли Николич
Original Assignee
Зе Боард Оф Трастиз Оф Зе Леланд Стэнфорд Джуниор Юниверсити
Зе Регентс Оф Зе Юниверсити Оф Калифорния
Алкахест, Инк.
Ю. С. Говернмент Эз Репрезентид Бай Зе Департмент Оф Ветеранс Эффэйрс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зе Боард Оф Трастиз Оф Зе Леланд Стэнфорд Джуниор Юниверсити, Зе Регентс Оф Зе Юниверсити Оф Калифорния, Алкахест, Инк., Ю. С. Говернмент Эз Репрезентид Бай Зе Департмент Оф Ветеранс Эффэйрс filed Critical Зе Боард Оф Трастиз Оф Зе Леланд Стэнфорд Джуниор Юниверсити
Publication of EA202091057A2 publication Critical patent/EA202091057A2/ru
Publication of EA202091057A3 publication Critical patent/EA202091057A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621—Extra-corporeal blood circuits
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/07—Proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)

Abstract

Предлагаются способы лечения взрослого млекопитающего от нарушения, ассоциированного со старением. Аспекты способов включают в себя снижение уровня 2-микроглобулина (B2M) у млекопитающего в степени, достаточной для лечения млекопитающего от нарушения, ассоциированного со старением. Ряд нарушений, ассоциированных со старением, можно лечить посредством практического осуществления способов, причем данные нарушения включают в себя когнитивные нарушения.
EA202091057A 2015-05-18 2016-05-17 Способы и композиции для лечения нарушений, ассоциированных со старением EA202091057A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562163222P 2015-05-18 2015-05-18

Publications (2)

Publication Number Publication Date
EA202091057A2 true EA202091057A2 (ru) 2020-12-30
EA202091057A3 EA202091057A3 (ru) 2021-03-31

Family

ID=57320543

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201792437A EA035799B1 (ru) 2015-05-18 2016-05-17 Способ лечения взрослого млекопитающего от когнитивного нарушения, ассоциированного со старением
EA202091057A EA202091057A3 (ru) 2015-05-18 2016-05-17 Способы и композиции для лечения нарушений, ассоциированных со старением

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201792437A EA035799B1 (ru) 2015-05-18 2016-05-17 Способ лечения взрослого млекопитающего от когнитивного нарушения, ассоциированного со старением

Country Status (11)

Country Link
EP (2) EP3892315A1 (ru)
JP (2) JP7134089B2 (ru)
KR (1) KR20180030965A (ru)
CN (2) CN107921188A (ru)
AU (4) AU2016265948B2 (ru)
CA (1) CA2984645C (ru)
EA (2) EA035799B1 (ru)
HK (1) HK1248153A1 (ru)
IL (1) IL255319B2 (ru)
NZ (1) NZ738184A (ru)
WO (1) WO2016187217A2 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017120461A1 (en) 2016-01-08 2017-07-13 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
MX2016007492A (es) 2013-12-09 2017-03-06 Univ Leland Stanford Junior Métodos y composiciones para el tratamiento de afecciones asociadas con el envejecimiento.
JP6921006B2 (ja) 2015-06-15 2021-08-18 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 老化関連症状を治療するための方法および組成物
DK3390367T3 (da) * 2015-12-15 2020-10-26 Univ Leland Stanford Junior Fremgangsmåde til forebyggelse og/eller behandling af aldersrelateret kognitiv funktionsnedsættelse og neuroinflammation
US10245285B2 (en) 2016-04-28 2019-04-02 Alkahest, Inc. Blood plasma and plasma fractions as therapy for tumor growth and progression
EA039316B1 (ru) 2016-10-24 2022-01-12 Алкахест, Инк. Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
US11040068B2 (en) 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
EP4299129A3 (en) 2017-04-26 2024-03-20 Alkahest, Inc. Dosing regimen for treatment of cognitive impairments with blood plasma products
AU2019364271A1 (en) 2018-10-26 2021-06-03 Alkahest, Inc. Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery
CN113081079B (zh) * 2021-03-30 2022-04-22 中国科学院生态环境研究中心 血桥限位器

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06104122B1 (ru) 1985-09-19 1994-12-21
EP0319862B1 (de) 1987-12-11 1994-01-12 Akzo Nobel N.V. Biocompatible Dialysemembran aus Cellulose mit erhöhter Beta-2-Microglobulinadsorption
FR2646607B1 (fr) 1989-05-03 1991-08-30 Inst Nat Sante Rech Med Anticorps monoclonaux anti-b2 microglobuline
US5614396A (en) 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
FR2685346B1 (fr) 1991-12-18 1994-02-11 Cis Bio International Procede de preparation d'arn double-brin, et ses applications.
US5240614A (en) 1992-01-10 1993-08-31 Baxter International Inc. Process for removing unwanted materials from fluids and for producing biological products
AU7623194A (en) 1993-09-03 1995-03-22 Vpi Holdings Ltd. Oligonucleotides with rna cleavage activity
EP0746614A1 (en) 1994-02-23 1996-12-11 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting the expression of disease related genes
FR2722411B1 (fr) 1994-07-18 1996-10-04 Union Pharma Scient Appl Immunonanoparticules revetues d'anticorps monoclonaux anti-beta2 microglobuline et leur utilisation pour la prophylaxie et/ou le traitement de pathologies dues a une infection par le virus hiv
US5780296A (en) 1995-01-17 1998-07-14 Thomas Jefferson University Compositions and methods to promote homologous recombination in eukaryotic cells and organisms
WO1996033266A1 (en) 1995-04-21 1996-10-24 Cell Genesys, Inc. Generation of large genomic dna deletions
US5776744A (en) 1995-06-07 1998-07-07 Yale University Methods and compositions for effecting homologous recombination
US5925544A (en) 1996-11-18 1999-07-20 Novo Nordisk A/S Method of homologous recombination followed by in vivo selection of DNA amplification
US5830698A (en) 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
US5948653A (en) 1997-03-21 1999-09-07 Pati; Sushma Sequence alterations using homologous recombination
US6416487B1 (en) 1997-07-30 2002-07-09 Renal Tech International Llc Method of removing beta-2 microglobulin from blood
US5904663A (en) 1997-07-30 1999-05-18 Braverman; Andrew Method of removing beta-2 microglobulin from blood
US20020159995A1 (en) 1997-07-30 2002-10-31 Renal Tech International Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood, generated as a result of extracorporeal blood processing
US7066900B2 (en) 1998-12-23 2006-06-27 Life Therapeutics Removal of metabolic components from blood
AUPP790898A0 (en) 1998-12-23 1999-01-28 Life Therapeutics Limited Renal dialysis
AUPR748501A0 (en) 2001-09-04 2001-09-27 Life Therapeutics Limited Renal dialysis
WO2000043120A1 (en) 1999-01-22 2000-07-27 The Dow Chemical Company Surface modified divinylbenzene resin having a hemocompatible coating
AU2001245793A1 (en) 2000-03-16 2001-09-24 Cold Spring Harbor Laboratory Methods and compositions for rna interference
AU2002312329A1 (en) 2001-06-05 2002-12-16 The Regents Of The University Of California Modulating neuronal outgrowth via the major histocompatibility complex class i (mhc i) molecule
PT2280070E (pt) 2001-07-23 2015-10-29 Univ Leland Stanford Junior Métodos e composições para inibição mediada por iarn da expressão génica em mamíferos
US20030180811A1 (en) 2002-03-11 2003-09-25 Montero-Julian Felix A. Immunoassays for beta2-microglobulin
US7341721B2 (en) 2002-04-12 2008-03-11 The Board Of Trustees Of The University Of Arkansas β2-microglobulin (β2m) and anti-β2m binding agents as anti-cancer therapeutics
US7037276B2 (en) 2002-07-02 2006-05-02 Precision Medical Devices, Inc. Biopsy device
US20040127445A1 (en) 2002-08-28 2004-07-01 Chondrogene Limited Beta-2 microglobulin (B2M) and B2M related gene products for the regulation of osteoarthritis pathogenesis and chondrocyte proliferation
WO2004048583A2 (en) 2002-11-22 2004-06-10 Institut Clayton De La Recherche Compositions and systems for the regulation of genes
GB0307206D0 (en) 2003-03-28 2003-04-30 Axordia Ltd Hyperproliferation
WO2006130949A1 (en) 2005-06-08 2006-12-14 Replicor Inc. Anti amyloid-related disease molecules and their uses
US8211310B2 (en) 2006-11-20 2012-07-03 Cytosorbents, Inc. Size-selective polymer system
EP2216060B2 (en) * 2007-12-06 2021-03-17 Asahi Kasei Medical Co., Ltd. Porous hollow fiber membrane for blood treatment
CN102223896A (zh) 2008-08-07 2011-10-19 西塞医疗中心 抗-β-2-微球蛋白试剂及其用途
JP2012504650A (ja) 2008-10-02 2012-02-23 セルタクシス，インコーポレイテッド 免疫細胞の負の走化性の調節方法
US8754034B2 (en) 2009-02-06 2014-06-17 The Regents Of The University Of California Structure-based design of peptide inhibitors of amyloid fibrillation
US20130040844A1 (en) * 2010-01-28 2013-02-14 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers of aging for detection and treatment of disorders
US20130331327A1 (en) 2012-06-08 2013-12-12 Vittorio Bellotti Variant Beta2-microglobulin, characterization of the same and applications thereof
EP2781523A1 (en) 2013-03-18 2014-09-24 Miltenyi Biotec GmbH Lipophilic oligonucleotide analogs
CA3089881C (en) * 2013-11-26 2024-04-02 University Of North Texas Health Science Center At Fort Worth Personalized medicine approach for treating cognitive loss

Also Published As

Publication number Publication date
NZ738184A (en) 2019-09-27
AU2016265948A1 (en) 2018-01-04
HK1248153A1 (zh) 2018-10-12
IL255319B (en) 2022-11-01
EA201792437A1 (ru) 2018-04-30
AU2016265948B2 (en) 2018-12-06
EP3297702A4 (en) 2019-01-16
CN107921188A (zh) 2018-04-17
EP3892315A1 (en) 2021-10-13
JP7323561B2 (ja) 2023-08-08
AU2022221494A1 (en) 2022-09-29
CA2984645A1 (en) 2016-11-24
IL255319B2 (en) 2023-03-01
JP7134089B2 (ja) 2022-09-09
EA035799B1 (ru) 2020-08-12
AU2020210181B2 (en) 2022-05-26
EP3297702A2 (en) 2018-03-28
JP2021073264A (ja) 2021-05-13
WO2016187217A3 (en) 2017-01-05
AU2020210181A1 (en) 2020-08-13
CA2984645C (en) 2023-01-10
JP2018518530A (ja) 2018-07-12
WO2016187217A2 (en) 2016-11-24
AU2019201337A1 (en) 2019-03-21
AU2019201337B2 (en) 2020-05-14
EA202091057A3 (ru) 2021-03-31
IL255319A0 (en) 2017-12-31
AU2019201337B9 (en) 2020-05-21
CN116687969A (zh) 2023-09-05
KR20180030965A (ko) 2018-03-27

Similar Documents

Publication Publication Date Title
EA202091057A3 (ru) Способы и композиции для лечения нарушений, ассоциированных со старением
EA201890020A1 (ru) Способы и композиции для лечения ассоциированных со старением состояний
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
HUE058209T2 (hu) Módszerek az autizmus spektrum zavar és azzal összefüggõ tünetek kezelésére
EA201790737A1 (ru) Комбинированная терапия
MX2023006304A (es) Administracion de celulas t dise?adas para tratamiento de canceres en el sistema nervioso central.
IL290994A (en) Methods for diagnosis and treatment of behavior disorder
BR112017016772A2 (pt) bactérias probióticas recombinantes para uso no tratamento de uma disfunção inflamatória da pele e método para tratá-la
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
EA201990257A1 (ru) Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
IL290069A (en) Methods for treating eye conditions
IL267229A (en) Methods of treating ocular disorders
MX2017000306A (es) Metodos para tratar hipotension.
EA201991650A1 (ru) Способы лечения неврологических расстройств
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
BR112018007566A2 (pt) neuromodulação periférica dependente do estado para tratar disfunção da bexiga
EA201892297A1 (ru) Способы лечения холестатических и фибротических заболеваний
SG11202006618PA (en) Compositions and methods for treating retinal disorders
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
MX2017007207A (es) Tratamiento de afecciones oculares mediante el uso de celulas progenitoras.
WO2015138761A3 (en) Methods for treating peripheral nerve damage